CBP Modulates Sensitivity to Dasatinib in Pre-BCR<sup>+</sup> Acute Lymphoblastic Leukemia.

导出 OA

翻译打印收藏纠错

作者： Jesús,Duque-Afonso ^[1] ; Chiou-Hong,Lin ^[2] ; Kyuho,Han ^[1] ; David W,Morgens ^[3] ; Edwin E,Jeng ^[3] ; Ziming,Weng ^[3] ; Johan,Jeong ^[1] ; Stephen Hon Kit,Wong ^[4] ; Li,Zhu ^[1] ; Michael C,Wei ^[1] ; Hee-Don,Chae ^[1] ; Martin,Schrappe ^[5] ; Gunnar,Cario ^[5] ; Justus,Duyster ^[6] ; Xiangshu,Xiao ^[6] ; Kathleen M,Sakamoto ^[2] ; Michael C,Bassik ^[7] ; Michael L,Cleary ^[5]

作者单位： Department of Pathology, Stanford University School of Medicine, Stanford, California. ^[1] Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany. ^[2] Department of Genetics, Stanford University School of Medicine, Stanford, California. ^[3] Stanford Center for Genomics and Personalized Medicine, Stanford, California. ^[4] Department of Pediatrics, Stanford University School of Medicine, Stanford, California. ^[5] Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. ^[6] Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon. ^[7] Department of Pathology, Stanford University School of Medicine, Stanford, California. mcleary@stanford.edu. ^[8]